Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Binding of pro-prion to filamin A disrupts cytoskeleton and correlates with poor prognosis in pancreatic cancer
Chaoyang Li, … , Wei Xin, Man-Sun Sy
Chaoyang Li, … , Wei Xin, Man-Sun Sy
Published August 17, 2009
Citation Information: J Clin Invest. 2009;119(9):2725-2736. https://doi.org/10.1172/JCI39542.
View: Text | PDF
Research Article Oncology

Binding of pro-prion to filamin A disrupts cytoskeleton and correlates with poor prognosis in pancreatic cancer

  • Text
  • PDF
Abstract

The cellular prion protein (PrP) is a highly conserved, widely expressed, glycosylphosphatidylinositol-anchored (GPI-anchored) cell surface glycoprotein. Since its discovery, most studies on PrP have focused on its role in neurodegenerative prion diseases, whereas its function outside the nervous system remains unclear. Here, we report that human pancreatic ductal adenocarcinoma (PDAC) cell lines expressed PrP. However, the PrP was neither glycosylated nor GPI-anchored, existing as pro-PrP and retaining its GPI anchor peptide signal sequence (GPI-PSS). We also showed that the PrP GPI-PSS has a filamin A–binding (FLNa-binding) motif and interacted with FLNa, an actin-associated protein that integrates cell mechanics and signaling. Binding of pro-PrP to FLNa disrupted cytoskeletal organization. Inhibition of PrP expression by shRNA in the PDAC cell lines altered the cytoskeleton and expression of multiple signaling proteins; it also reduced cellular proliferation and invasiveness in vitro as well as tumor growth in vivo. A subgroup of human patients with pancreatic cancer was found to have tumors that expressed pro-PrP. Most importantly, PrP expression in tumors correlated with a marked decrease in patient survival. We propose that binding of pro-PrP to FLNa perturbs FLNa function, thus contributing to the aggressiveness of PDAC. Prevention of this interaction could provide an attractive target for therapeutic intervention in human PDAC.

Authors

Chaoyang Li, Shuiliang Yu, Fumihiko Nakamura, Shaoman Yin, Jinghua Xu, Amber A. Petrolla, Neena Singh, Alan Tartakoff, Derek W. Abbott, Wei Xin, Man-Sun Sy

×

Figure 2

PrP in the PDAC cell lines exists as pro-PrP.

Options: View larger image (or click on image) Download as PowerPoint
PrP in the PDAC cell lines exists as pro-PrP.
(A) Immunoblots show PrP f...
(A) Immunoblots show PrP from WV cells has a MW of 34 kDa, while PrP from the PDAC cell lines has a MW of 26 kDa. A recombinant PrP (rPrP) produced in E. coli is included as a control and MW marker. (B) Immunoblots show treatment of PrP from WV cells with endoglycosidase-F (PNGase F) reduces its MW from 34 kDa to 25.5 kDa. But identical treatment does not change the mobility of PrP from the PDAC cell lines. Deglycosylated PrP from WV cells migrated slightly faster than PrP from the PDAC cell lines (dashed arrows). (C) Immunoblots show PrP from WV cells is sensitive to PI-PLC, as shown by the appearance of a smaller PrP species (bottom arrow) in addition to the PNGase F–treated species (top arrow), but PrP from the PDAC cell lines is resistant to PI-PLC. (D) Immunoblots show that while PrP from the 2 PDAC cell lines is sensitive to CPase B, PrP from WV cells is resistant. CD55 from BxPC 3 cells is also resistant to CPase B. (E) Immunoblots show a rabbit antiserum specific for the PrP GPI-PSS reacts with recombinant pro-PrP (rPro-PrP23–253) but not with recombinant mature PrP (rPrP23–231). The anti–GPI-PSS antiserum also reacts with pro-PrP from the PDAC cell lines but does not react with the PrP from WV cells.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts